Pepcid Ingredient Famotidine Being Tested as COVID-19 Treatment

APRIL 27, 2020 — COVID-19 sufferers at some New York hospitals are getting heartburn drugs

The patients are being given famotidine, the active ingredient in Pepcid, and early results from the trial could be available in the next few weeks.

APRIL 27, 2020 — COVID-19 sufferers at some New York hospitals are getting heartburn drugs as portion of a scientific demo.

The sufferers are staying presented famotidine, the lively ingredient in Pepcid, and early effects from the demo could be offered in the subsequent few weeks, in accordance to Dr. Kevin Tracey, president of Feinstein Institutes for Professional medical Exploration at Northwell Health and fitness, which has 23 hospitals in the New York Metropolis spot, CNN claimed.

The scientific demo has 187 sufferers so much, with the goal of enrolling 1,200, Tracey stated.

He and his colleagues decided to evaluate the use of famotidine in COVID-19 sufferers soon after observations in China that some sufferers using the drug experienced improved outcomes than those not using the drug, CNN claimed.

“We will not know if it has any benefit. We genuinely will not. I swear we will not,” Tracey stated. “Folks are hoping for anything at all. But we need to do this scientific demo.”

He noted that the sufferers in the scientific demo are in the healthcare facility getting mega-doses of famotidine intravenously — doses about nine instances higher than a man or woman would commonly just take for heartburn, CNN claimed.

“You should not go to the drugstore and just take a bunch of heartburn drugs,” Tracey warned.

Copyright © 2020 HealthDay. All legal rights reserved.


What is the Wuhan coronavirus?
See Respond to

Leave a Reply

Your email address will not be published. Required fields are marked *